Summary
Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggesting the need for further clinical development of Notch pathway modulators in men with metastatic prostate cancer.
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Author Manuscript Published OnlineFirst on August 25, 2015; DOI: 10.1158/1078-0432. CCR-15-1613 In this issue of Clinical Cancer Research, Cui and colleagues report the additive efficacy of a gamma secretase inhibitor (GSI), PF-03084014, together with docetaxel both in vitro and in murine models of prostate cancer, including soft tissue growth and growth and survival of tumors in bone (1) . Docetaxel was the first chemotherapeutic to increase overall survival for castration resistant prostate cancer (2), but resistance to docetaxel develops commonly after about 6 months of therapy. In addition, recent data using docetaxel with androgen-deprivation therapy in the castration-sensitive metastatic setting has suggested more dramatic improvements in survival (3, 4) . Several recent studies have implicated Notch signaling in docetaxel resistance, particularly in promoting epithelial plasticity, dedifferentiation, and stemness properties in prostate cancer (5, 6) . These studies demonstrated that targeting these stemness pathways significantly delayed prostate cancer progression, particularly with co-targeting of the Hedgehog/GLI and Notch pathways. In addition, Notch signaling has been implicated through gene expression profiling with high grade localized prostate cancer in patients (5) .
Trials attempting to combine docetaxel with novel agents have been fraught with failure in over a dozen phase 3 trials, despite a range of successes in preclinical models of prostate cancer (7) . While some of these failures may be attributable to challenges in decision-making in early clinical development and a lack of surrogate endpoints for early drug development decision-making, a major obstacle has also been the lack of suitable predictive preclinical models and appropriately designed experiments that recapitulate the bone microenvironment. The majority of men with lethal prostate cancer have bone metastases, while the majority of animal 
of function mutations in JAG1 and NOTCH2 in cholangiocarcinoma and hepatocellular carcinoma (10) . In addition, Notch may act as a tumor suppressor in the skin and may be important for gastrointestinal tract maintenance, illustrating some challenges in therapeutic targeting.
The Notch receptor is tightly regulated in the cell, posing potential opportunities for pharmacologic interference (Fig. 1) . Several proteolytic cleavage steps of the receptor by furin, ADAM17 secretase, and γ-secretase could be inhibited. inhibiting xenograft tumor growth. The investigators made bone xenografts with these cell lines, and showed that GSI monotherapy was effective at inhibiting tumor growth, while docetaxel alone was not. Through a series of elegant experiments, they showed that these tumor-inhibiting effects occurred through cellular mechanisms of decreasing cellular proliferation, blocking new blood vessel formation, and increasing apoptosis (Fig. 1) . This was accompanied by modulation of parallel signaling pathways critical to prostate cancer progression, such as the PI3K/AKT pathway, BCL-2, MEK and ERK phosphorylation, and reversal of the epithelial-to-mesenchymal transition. Interestingly, Notch inhibition led to a reduction in stemness phenotypes and prostasphere formation, while docetaxel increased these properties. While still limited by the models studied and the lack of a spontaneous bone-metastatic prostate cancer model, and understanding that cell lines and mice are not men, these data suggest that further evaluation of this combination is worthy of study should a suitable drug candidate emerge for clinical testing.
There are multiple questions that deserve attention in future studies of this pathway. One is whether Notch inhibition with docetaxel reduces or prevents prostate cancer metastasis as compared to reduction in the size of existing bone metastases, and whether this combination is additive in both the castration resistant and castration sensitive settings, in order to inform on the appropriate clinical setting for study. Second is whether GSIs can be safely delivered to patients without promoting skin or gastrointestinal toxicity, while delivering pharmacodynamically active doses to tumors. Third is the mechanism(s) of 
